Form 4: Dolby Laboratories CEO Kevin Yeaman Executes Stock Transactions
SEC Form 4 Filing
Dolby Laboratories CEO Kevin Yeaman exercised stock options and sold shares, both directly and indirectly through a family trust.
Summary
- Kevin Yeaman, the President and CEO of Dolby Laboratories, engaged in multiple transactions involving the company's Class A Common Stock.
- On November 25, 2024, Mr. Yeaman exercised options to acquire 50,000 shares at $62.32 per share and sold 49,104 shares at a weighted average price of $80.5277, and a further 896 shares at a weighted average price of $81.1764.
- On November 26, 2024, he exercised options to acquire 7,888 shares at $62.32 per share and sold 7,888 shares at $80.19 per share.
- These transactions were conducted both directly and indirectly through the Kevin and Rachel Yeaman Family Trust.
- Following these transactions, Mr. Yeaman directly holds 120,320 shares of Class A common stock underlying restricted stock units and indirectly holds 83,721 shares through the trust, as well as 2.5592 shares held by a son.
Sentiment
Score: 5
Explanation: The document is a neutral report of stock transactions, with no indication of positive or negative sentiment. It is a routine filing.
Industry Context
This filing is a routine disclosure of insider transactions, which is common for publicly traded companies. It provides transparency into the trading activities of key executives.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies in the US, and this filing is consistent with those requirements.
- The transactions are typical for executives who receive stock options as part of their compensation package.
- The sale prices are within the normal trading range for the stock at the time of the transactions.
Stakeholder Impact
- The transactions may have a minor impact on the stock price, but are unlikely to significantly affect stakeholders.
Key Dates
| Date | Description |
|---|---|
| 05/14/2009 | Date of the Kevin and Rachel Yeaman Family Trust. |
| 12/15/2020 | End date of the three-year performance period for a performance-based stock option award. |
| 10/25/2024 | Date of the earliest transaction reported in the document. |
| 11/25/2024 | Date of multiple stock option exercises and sales. |
| 11/26/2024 | Date of further stock option exercises and sales. |
| 11/27/2024 | Date the form was signed. |
Keywords
stock options, insider trading, stock sales, Form 4, Dolby Laboratories, Kevin Yeaman, equity securities, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.